Felty’s Syndrome by Gorodetskiy, Vadim
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










Felty’s syndrome (FS) is an uncommon subset of seropositive rheumatoid 
arthritis (RA) complicated by neutropenia with or without splenomegaly. The 
pathogenesis of neutropenia in FS is still not fully understood, but it is believed that 
the principal cause is neutrophil survival defect. Autoantibodies against peptidylar-
ginine deiminase type 4 deiminated histones, glucose-6-phosphate isomerase, and 
eukaryotic elongation factor 1A-1 antigen may contribute to neutropenia develop-
ment in FS patients. Splenic histology in FS shows non-specific findings and spleen 
size do not correlate with neutropenia. Cases of T-cell large granular lymphocytic 
leukemia with low tumor burden in blood and concomitant RA are clinically 
indistinguishable from FS and present a diagnostic challenge. Examination of T-cell 
clonality, mutations in signal transducer and activator of transcription 3 gene, and 
the number of large granular lymphocytes in the blood can establish a correct diag-
nosis. Optimal approaches to therapy for FS have not been developed, but the use of 
rituximab seems promising. In this chapter, the epidemiology, pathogenesis, clinical 
manifestations, differential diagnosis, and treatment options for FS are discussed.
Keywords: Felty’s syndrome, rheumatoid arthritis, neutropenia, splenomegaly,  
large granular lymphocyte leukemia
1. Introduction
In 1924, at Johns Hopkins Hospital, American physician Augustus Felty 
described five unusual cases with features of chronic arthritis, splenomegaly, and 
striking leukopenia [1]. In 1932, the eponym “Felty’s syndrome (FS)” was first 
used by Hanrahan and Miller to describe these cases [2]. Currently, FS is consid-
ered an uncommon subset of seropositive rheumatoid arthritis (RA) complicated 
by neutropenia and splenomegaly [3]. Although splenomegaly represents one 
characteristic of the triad that defines FS, it is not an absolute requirement of FS 
diagnosis [4, 5]. T-cell large granular lymphocyte (T-LGL) leukemia in the setting 
of RA is the condition most likely to be confused with FS. Studies on FS should be 
considered with the caveat that almost all were performed without a study of T-cell 
clonality and, therefore, could include cases of RA-associated T-LGL leukemia (see 
“Diagnosis and differential diagnosis”).
2. Epidemiology
About 1% to 3% of patients with RA develop FS [6]. However, with the evolution 
of RA pharmacotherapy, the frequency of FS has decreased substantially [7]. The 




There is firm evidence that the HLA-DRB1*04 genotype is a risk factor for FS 
development [9]. The exact pathophysiological mechanisms leading to development 
of neutropenia and splenomegaly in FS are unknown. It is believed, though, that 
neutrophil survival defect is the main cause of neutropenia [8, 10]. Several auto-
antibodies have been found in the serum of FS patients with higher frequency or at 
higher titers in comparison with seropositive RA patients without FS, which may 
contribute to neutropenia development, including:
• autoantibodies to H3, H4, and H2A histones deiminated by peptidylarginine 
deiminase type 4 [11];
• autoantibodies against glucose-6-phosphate isomerase [12];
• autoantibodies against eukaryotic elongation factor 1A-1 antigen [13];
• circulating immune complexes [14].
Autoantibodies against granulocyte colony-stimulating factor (G-CSF) were 
found in 73% patients with FS [15]. However, given that, in most cases, bone mar-
row in FS reveals normal myeloid cellularity or myeloid hyperplasia with increased 
granulopoiesis, relative excess of immature forms, and apparent lack of mature 
myeloid elements [8], the pathogenetic significance of anti-G-CSF antibodies in 
neutropenia development in patients with FS is unclear.
Some researchers question the significance of spleen sequestration/destruction 
in neutropenia pathogenesis [8]. However, neutrophils are found in periarteriolar 
lymphoid sheaths of the spleen even in patients with severe neutropenia [16]. In 
addition, removal of the spleen leads to restoration of normal neutrophil counts in 
most patients with FS.
4. Clinical manifestations
Clinical manifestations of FS and the frequency of signs/symptoms based on 
literature data [5, 14, 17–19] are presented in Table 1.
FS usually develops 10–15 years after RA presentation [14, 20], but in rare 
instances, neutropenia and splenomegaly may precede an arthritis history  
(non-articular Felty’s syndrome) [21–24].
The erosive process in FS is typically severe, but this is related to the duration of 
RA before the onset of neutropenia and splenomegaly [6]. RA with FS is associated 
with more frequent and severe extra-articular manifestations than RA without FS 
[14, 20]. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) 
antibodies are associated with severe extra-articular manifestations in patients with 
RA [25]. This is consistent with the finding that the vast majority of patients with 
FS have high titers of RF [14]. In our cohort of 25 patients with FS with a median 
duration of RA prior to FS diagnosis of 7 years, erosive arthritis at the time of FS 
diagnosis was detected in 77% of the patients. RF was within the normal range in 
only two cases, but the anti-CCP titers in these patients were highly positive [26].
Neutropenia (absolute neutrophil count of less than 1.500–2.000/μL) without a 
clearly identified cause is required, by definition, for the FS diagnosis. Neutropenia 
can manifest as increased frequency and severity of bacterial infections. However, 
despite reduced absolute neutrophil counts, patients with FS can remain free of 




Splenomegaly is present in over 90% of patients with FS, but the spleen size does 
not correlate with neutropenia [14, 17, 19]. Splenic histology in FS shows non-
specific findings (Figure 1). The red pulp shows expanded sinuses as well as the 
pulp cords, and an increased number of macrophages and plasma cells. The white 
pulp follicles are usually hyperplastic [18, 27, 28]. It is possible that portal hyperten-
sion secondary to nodular regenerative hyperplasia of the liver contributes to spleen 
enlargement in some patients with FS [29].
5. Diagnosis and differential diagnosis
FS should be suspected in a patient with RA, unexplained neutropenia, and 
splenomegaly. There is a wide range of pathologies in patients with RA that can 
manifest with neutropenia with or without splenomegaly. FS is a clinical diagnosis, 
Figure 1. 
Spleen histological examination in a patient with Felty’s syndrome. (A) The spleen shows preservation of the 
white pulp with prominent germinal centers and lymphocytic infiltration of the red pulp (H&E, ×100).  
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and there is no specific single diagnostic test to confirm or exclude it; therefore, FS 
is essentially a diagnosis of exclusion.
Neutropenia caused by drug therapy (drug-induced neutropenia) should be 
ruled out first. The most important treatment of drug-induced neutropenia is to 
withdraw the causative drug. The average time for full recovery of the neutrophil 
count is 9 days (range, 9–24 days) [30]. Methotrexate, cyclophosphamide, azathio-
prine, sulfasalazine, leflunomide, tocilizumab, tumor necrosis factor (TNF)-alpha 
antagonists, antimalarial medications, analgesics, and nonsteroidal anti-
inflammatory drugs are the most common causes of drug-induced neutropenia in 
patients with RA [28]. It is important to keep in mind that unlike with other drugs, 
rituximab-induced neutropenia occurs after a median period of 4.5 months (range, 
3–6.5 months) after the last rituximab infusion [31].
T-LGL leukemia is a rare type of mature T-cell neoplasm characterized by the 
clonal expansion of large granular lymphocytes (LGLs) and, in most cases, has 
indolent clinical course. Typical features of T-LGL leukemia include the increase in 
the number of peripheral blood LGLs, cytopenia (most commonly neutropenia), 
and variable splenomegaly. A peculiar feature of T-LGL leukemia is its associa-
tion with RA, which occurs in 17–28% of patients with T-LGL leukemia [32, 33]. 
Historically, a definitive diagnosis of T-LGL leukemia required the increase in the 
number of LGLs in peripheral blood greater than 2 × 109/L, but it is now recognized 
that a lower count (range, 0.4–2 × 109/L) may be compatible with the diagnosis 
[34–36].
Cases of T-LGL leukemia in the setting of RA (RA-associated T-LGL leukemia) 
with low LGL count in peripheral blood and concomitant neutropenia are clinically 
indistinguishable from FS and diagnostically challenging. RA-associated T-LGL 
leukemia and FS are distinguished in clinical practice by evaluation of rearrange-
ments of the T cell receptor (TCR) gamma and TCR beta genes in the blood and/or 
in the bone marrow. The monoclonal rearrangements of the TCR genes (T-cell clon-
ality) are present in T-LGL leukemia but not in FS (Figure 2) [3, 8, 37]. However, 
Figure 2. 
Evaluation of T-cell clonality based on rearrangements of the T-cell receptor (TCR) genes. (A) TCR genes 





there is considerable discussion regarding the significance of dominant T-cell 
clones as a hallmark of T-cell malignancy because clonal populations of T-cells are 
observed both in healthy individuals and in exuberant reactive responses [38–43]. 
Activating somatic mutations in the signal transducer and activator of the tran-
scription 3 (STAT3) gene and an increase in the number of LGLs above 2 × 109/L 
were detected in RA-associated T-LGL leukemia but not in FS (39% vs. 0% and 
21% vs. 0%, respectively) [26]. In addition, the expression of the CD57 antigen and 
the aberrant (diminished or absent) expression of CD5 on cytotoxic CD3 + CD8+ 
T-lymphocytes are more typical for T-LGL leukemia than in the polyclonal expan-
sion of cytotoxic T-lymphocytes in FS [26]. In contrast, it seems that the current 
criteria for bone marrow involvement in T-LGL leukemia do not seem to be suf-
ficiently specific to distinguish it from FS [8, 26].
Aplastic anemia, myelodysplastic syndromes, or acute leukemia can sometimes 
present with isolated neutropenia. To rule out these pathologies, a bone marrow 
examination should be considered. In rare cases, cirrhosis, amyloidosis, lymphomas 
involving spleen, sarcoidosis, or infections can lead to splenomegaly in patients 
with RA.
6. Management
In two earlier analyzes of survival in FS, 5-year mortality ranged from 25% 
to 36% [5, 44]; however, recent data regarding the prognosis of FS are not avail-
able. The treatment goal in FS is a reversal of the neutropenia to prevent recurrent 
bacterial infections and sepsis, which is the leading cause of death in patients with 
FS. The treatment strategy for FS is not evidence-based because of the lack of 
controlled trials.
Methotrexate (MTX) is considered the first-line therapy for treatment of 
FS based on case reports and case series data. Low doses of MTX (up to 25 mg 
once a week) can improve both joint diseases and neutropenia, usually within 
1–2 months.
One recent literature review supported the use of rituximab (RTX) as a 
second-line therapy. A sustained increase in the absolute number of neutrophils 
was observed in 62.5% of FS patients during the 3 months following one cycle of 
RTX treatment [45]. The appropriate dosing schedule of RTX for treatment of FS 
remains uncertain, but most often patients receive two 1000 mg doses separated by 
15 days [46]. Some patients had a recurrence of neutropenia after RTX treatment, 
indicating that in some cases a sustained response may require maintenance therapy 
with RTX.
There is very limited evidence regarding the leflunomide efficacy in FS [47]. 
TNF-alpha inhibitors (adalimumab, ethanercept, and infliximab) are ineffective 
in FS [45].
Splenectomy maintained normal neutrophil counts in 80% of patients with FS 
[10]. However, the indications for splenectomy are now limited because of effective 
medications and the risk of post-splenectomy sepsis.
The results of treatment with glucocorticoids (GCs) in patients with FS are 
variable. GCs can provide a rapid improvement in neutrophil count by stimulat-
ing the release of mature cells from the bone marrow and mobilizing them from 
the marginal pool, thus, creating the effect of increasing their absolute number. 
However, to achieve a real clinical effect, high doses and prolonged use of GCs may 
be required, which increases the risk of infection in patients with FS.
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7. Conclusion
Although nearly 100 years have passed since the first description of FS, this 
pathology remains a mystery in many aspects. The pathogenetic mechanisms 
underlying neutropenia and spleen enlargement in these patients are poorly 
understood. Optimal approaches to therapy for this rare disorder have not been 
developed, but the use of rituximab seems promising.
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